Where Chinese Investors Meet Global Investment News and Opportunities

中國投資者探索環球投資新聞及機遇

Eastwood Bio-medical Canada Inc. Introduces New Product For Memory and Cognitive Function in Adults

August 9, 2018 – Richmond, British Columbia – Eastwood Bio-medical Canada Inc. (TSX- V: EBM) (the “Company”) is pleased to announce the introduction of nine new products. Since the Company last announced the introduction of new products on May 4, 2018, Health Canada has granted further nine new Natural Product Numbers (NPNs), including one for a product named Eleotin® Neuro Formula. Eleotin® Neuro Formula helps to enhance cognitive function and memory in adults.

Yunji Kim, President and CEO, commented, “We are particularly pleased with this development. Directly addressing and providing solutions for memory loss and dementia opens up significant additional new target markets.

Scientific institutions like the National Institute of Health (NIH), and numerous media outlets have reported that cognitive diseases such as Alzheimer’s are another form of diabetes, going as far as calling the condition Type III diabetes. Our own products have long been praised as the ‘World’s #1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada.’ Accordingly, it was presumed that our company’s core technologies were highly likely to help patients showing symptoms of cognitive and memory degeneration. Several hundred clients have already provided testimonials with anecdotes about Eleotin® products significantly improving their cognitive health. With our recent approval, we can officially start providing the market with a safe product specifically for cognitive health.”

About Eastwood Bio-Medical Canada, Inc.:

The Company is a Vancouver based biotechnology company whose Eleotin® brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin® was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on the cause, cure, and prevention of Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-

medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin® products have been endorsed by thousands of doctors and diabetes associations around the globe.

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.

For further information, please contact:

Eastwood Bio-Medical Canada Inc.

Yunji Kim, President and Chief Executive Officer Telephone: (604) 247-2100

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Do NOT follow this link or you will be banned from the site!